Glioblastoma is the most common and lethal primary malignant brain tumor in adults. The tumor suppressor gene PTEN is deleted, mutated or hypermethylated in more than 60% of glioblastoma cases resulting in hyperactivation of the phosphoinositide 3-kinase pathway, which leads to sustained PI(3,4,5)P 3 signaling, and thereby hyperactivation of Akt and other effectors. PI(3,4,5)P 3 is also hydrolyzed to PI(3,4)P 2 by inositol polyphosphate 5-phosphatases such as SKIP, but the role this pathway has in glioblastoma is unknown. Microarray expression profiling of SKIP in human glioblastoma has revealed both increased and decreased SKIP gene expression. Here we have screened PTEN-deficient glioblastoma for SKIP protein expression by immunohistochemistry and report that SKIP expression is increased in some cases or decreased relative to normal brain. Using the U-87MG PTEN-deficient cell line we show that SKIP knockdown did not further enhance cell proliferation or survival. However, SKIP overexpression in U-87MG cells suppressed anchorage-independent cell growth and growth factor-induced PI(3,4,5)P 3 /Akt signaling. Although, SKIP knockdown did not affect cell proliferation or survival, cell migration was significantly retarded, associated with significantly increased PI(4,5)P 2 signals, and decreased phosphorylation of the actin-regulatory protein cofilin, a PI(4,5)P 2 -binding protein. Notably, overexpression of SKIP also inhibited migration of U-87MG cells to a similar degree as observed with PTEN reconstitution, however, via distinct mechanisms. PTEN reconstitution promoted sustained lamellipodia generation and focal adhesion formation. In contrast, SKIP overexpression reduced sustained lamellipodia formation, talin incorporation into focal adhesions and recruitment of PI(4,5)P 2binding proteins to the plasma membrane. Notably, analysis of two independent ONCOMINE microarray data sets revealed a significant correlation between increased SKIP mRNA expression in glioblastoma and improved long-term survival. Therefore, SKIP expression in glioblastoma may affect the local invasion of PTEN-deficient tumors.
INTRODUCTION
Primary glioblastoma is the most common malignant tumor of the brain, and affected individuals face a poor prognosis despite continuous advancement in diagnostic procedures and treatment. 1 Glioblastoma does not typically metastasize to secondary sites, but is locally invasive, and the infiltration of glioblastoma cells into adjacent brain tissue contributes to malignancy. 2 Dysregulated phosphoinositide 3-kinase (PI3K) signaling is prominent in glioblastoma. PI3K phosphorylates phosphatidylinositol 4,5-bisphosphate (PI(4,5)P 2 ) to transiently generate phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P 3 ) at the plasma membrane, leading to the activation of the serine/ threonine kinase Akt and other effectors that drive cell proliferation, growth and survival. 3 PI(3,4,5)P 3 and PI(4,5)P 2 also cooperatively regulate cytoskeletal reorganization and thereby cell migration via recruitment and regulation of actin-binding and membrane-linkage proteins. 4 PTEN is a phosphoinositide 3-phosphatase that hydrolyzes PI (3,4,5)P 3 to generate PI(4,5)P 2 , thus directly opposing PI3K signaling. 5 PTEN deletion, mutation or methylation occurs in more than 60% of glioblastoma. 6 Furthermore, PTEN loss in glioblastoma has been reported at the DNA, mRNA and protein level. [7] [8] [9] [10] PTEN is arguably the primary phosphoinositide phosphatase opposing PI3K signaling; however, PI(3,4,5)P 3 is also degraded by inositol polyphosphate 5-phosphatases (5-phosphatases) to generate PI(3,4)P 2 , which is subsequently hydrolyzed by 4-phosphatases to form PI(3)P. 11 SKIP is a widely expressed 5-phosphatase that degrades both PI(3,4,5)P 3 and PI(4,5)P 2 , generating PI(3,4)P 2 and PI(4)P, respectively. [12] [13] [14] [15] [16] [17] Targeted disruption of murine Skip (Inpp5k) is embryonically lethal before embryonic day 10.5 for unknown reasons. 16 Expression of SKIP suppresses PI(3,4,5)P 3 signaling and Akt activation in insulinresponsive cells, [14] [15] [16] however, its role in regulating cancer cell proliferation and migration is unknown. There is some evidence that SKIP shows altered expression in brain cancer. The SKIP (INPP5K) locus 17p13.3 is a region that is deleted or hypermethylated in astrocytoma, medulloblastoma and neuroectodermal tumors. [18] [19] [20] Furthermore, large-scale genetic screens reveal SKIP mRNA or DNA levels that can be either increased or decreased in glioblastoma relative to normal tissue. 7, 8, 10, [21] [22] [23] Whether alterations in SKIP expression occur in PTEN-null glioblastoma that impact on tumor progression remains unexplored. In this study, we screened PTEN-deficient glioblastoma for SKIP protein expression and assessed the impact of SKIP knockdown or overexpression in the PTEN-null U-87MG glioblastoma cell line. These studies reveal that SKIP exhibits altered expression in PTEN-null glioblastoma and this may inhibit glioblastoma cell migration via PI(4,5)P 2 -dependent regulation of the actin cytoskeleton.
RESULTS

SKIP is differentially expressed in human glioblastoma
There is evidence from high-throughput microarray screens comparing gene expression in glioblastoma with normal tissue that the 5-phosphatase SKIP can exhibit either increased or decreased expression at the DNA or mRNA level. 7, 8, 10, [21] [22] [23] Notably, comparative analysis of 7689 genes in 22 cases of glioblastoma revealed that SKIP mRNA is located in the top 1% of genes with Figure 1 . SKIP deficiency does not alter glioblastoma cell proliferation. (a) mRNA was extracted from U-87MG cells transfected with control or one of two independent SKIP siRNAs. mRNA was analyzed by qRT-PCR and graphically represented as mean percent mRNA ± s.e.m. of four independent experiments. Statistical analysis was performed with one-way analysis of variance (ANOVA) followed by Tukey's post hoc test. **P o0.01 compared with control siRNA. (b) NP-40-soluble fractions 48 h post transfection were subjected to immunoblot analysis using the indicated antibodies. (c) Quantification of SKIP protein was determined by densitometry relative to β-tubulin, expressed as mean percentage SKIP expression ± s.e.m. of four independent experiments, standardized to non-transfected control cells. Statistical analysis was performed with one-way ANOVA followed by Tukey's post hoc test. **P o0.01 compared with control siRNA. (d) Cell proliferation in SKIP-knockdown U-87MG cells was assessed by BrdU incorporation. Representative fluorescent images of U-87MG cells transfected with SKIP siRNA or scrambled control, grown in DMEM containing 10% (v/v) serum, serum-free media or plated on fibronectin for 24 or 48 h before BrdU incorporation. Fixed cells were incubated with affinity-purified antibodies directed to BrdU and counterstained with propidium iodide. Scale bar, 20 μm. (e-g) Quantification of cell proliferation was determined by counting the number of BrdU-positive cells in six separate fields relative to total cell number, expressed as mean percentage BrdU incorporation ± s.e.m. of three independent experiments. Statistical analysis was performed with one-way ANOVA followed by Tukey's post hoc test. P-values not significant.
increased expression in glioblastoma compared with normal brain tissue. 24 Conversely, it also falls within the top 5% of 8603 genes with decreased expression in 28 cases of glioblastoma. 25 However, the protein expression profile of SKIP in glioblastoma is unknown and the regulatory role SKIP has in glioblastoma pathogenesis has not been reported. Therefore, we examined SKIP protein expression versus PTEN in 43 cases of clinically graded human glioblastoma on tissue arrays (US Biomax, Rockville, MD, USA) by immunohistochemical analysis. The PTEN antibody (clone 138G6; Cell Signaling Technologies, Danvers, MA, USA) has been characterized previously. 26 The SKIP antibody was generated and characterized previously 12 and also here ( Figure 1b ).
Representative glioblastoma cases demonstrating PTEN or SKIP antibody immunoreactivity are shown (Figure 2a ). Vascular endothelial cells displayed positive immunoreactivity to both PTEN and SKIP antibodies that was comparable to normal cerebrum staining, and thus served here as an internal positive control. 9, 27 Antibody immunoreactivity was scored according to previously established protocols. 28 Glioblastoma cases were graded as +2 when staining intensity of tumor cells was equivalent to that of vascular endothelial cells in the same section; +1, if tumor cell staining was diminished relative to endothelial cells; and +3, where staining intensity of tumor cells was increased relative to endothelial cells ( Supplementary   Figure 2 . SKIP is differentially expressed in human glioblastoma. Representative images of PTEN (ai, aii, aiii) or SKIP (aiv, av, avi, avii) antibody immunoreactivity of normal cerebrum or clinically graded samples of grade IV human glioblastoma tumor sections. Vascular endothelial cells displayed positive immunoreactivity to both PTEN and SKIP antibodies and were utilized here as an internal positive control. Antibody immunoreactivity was scored according to previously established protocols. 9 Glioblastoma cases were graded as +2 if the staining intensity of tumor cells was equivalent to that of vascular endothelial cells; +1, if tumor cell staining was diminished relative to endothelial cells; and +3, if the staining intensity of tumor cells was increased relative to endothelial cells. (ai) Normal cerebrum with PTEN antibody immunoreactivity equivalent to endothelial cells (grade = +2). (aii) Glioblastoma section with PTEN antibody immunoreactivity equivalent to endothelial cells (grade = +2). (aiii) Glioblastoma section with decreased PTEN antibody immunoreactivity relative to endothelial cells (grade = +1). (aiv) Normal cerebrum with SKIP antibody immunoreactivity equivalent to endothelial cells (grade = +2). (av) Glioblastoma section with SKIP antibody immunoreactivity equivalent to endothelial cells (grade = +2). (avi) Glioblastoma section with decreased SKIP antibody immunoreactivity relative to endothelial cells (grade = +1). (avii) Glioblastoma section with increased SKIP antibody immunoreactivity relative to endothelial cells (grade = +3). Scale bar, 100 μm. (bi, bii, biii) Representative images of PTEN-deficient grade IV human glioblastoma sections, showing decreased PTEN antibody immunoreactivity relative to endothelial cells (grade = +1). (biv) PTEN-deficient grade IV human glioblastoma sections exhibiting decreased SKIP antibody immunoreactivity relative to endothelial cells (grade = +1). (bv) PTEN-deficient glioblastoma showing SKIP antibody immunoreactivity equivalent to endothelial cells (grade = +2). (bvi) PTEN-deficient glioblastoma displaying increased SKIP antibody immunoreactivity relative to endothelial cells (grade = +3). Scale bar, 100 μm. Figure 1 ). Representative images of normal cerebrum tissue with immunoreactivity to PTEN or SKIP equivalent to endothelial cell staining (+2) are shown ( Figure 2ai and iv, respectively). In accordance with previous reports, 9 58 .14% (25/43) of grade IV glioblastoma cases showed decreased PTEN antibody immunoreactivity compared with endothelial cells (+1) ( Figure 2aiii ; Table 1 ). 30.23% (13/43) of glioblastoma cases showed reduced SKIP antibody immunoreactivity (+1) ( Figure 2avi ; Table 1 ) and 27.91% (12/43) exhibited increased SKIP antibody staining (+3) ( Figure 2avii ; Table 1 ). 41.86% (18/43) of glioblastoma cases exhibited SKIP antibody staining equivalent to endothelial cells (+2) ( Figure 2av ; Table 1 ). No correlation between PTEN and SKIP antibody immunoreactivity was detected in this cohort, however, in 25 cases of PTEN-deficient glioblastoma, 28% (7/25) showed decreased SKIP antibody immunoreactivity ( Figure 2biv ; Table 2 ); 36% (9/25) exhibited increased SKIP antibody staining ( Figure 2bvi ; Table 2 ); and 36% (9/25) showed SKIP antibody staining equivalent to endothelial cells ( Figure 2bv ; Table 2 ). Thus, although immunohistochemistry cannot accurately quantitate protein expression, the variable SKIP immunoreactivity in PTENdeficient glioblastoma, coupled with previous gene array studies that show altered SKIP gene expression patterns, suggested that SKIP expression may be increased or decreased in glioblastoma, and does not correlate with PTEN expression. Therefore, we investigated the effects of SKIP under-or overexpression in PTENdeficient cell lines.
SKIP deficiency does not alter glioblastoma cell proliferation or survival
We next investigated the impact of SKIP knockdown on PTEN-null glioblastoma cell function. To this end, the effects of small interfering RNA (siRNA)-mediated silencing of SKIP on cell proliferation and survival were examined in the PTEN-deficient U-87MG glioblastoma cell line, which contains a splice mutation in intron 3 of PTEN, resulting in loss of PTEN protein. 29, 30 Approximately 80% SKIP knockdown was achieved as assessed by quantitative reverse transcriptase-PCR or SKIP immunoblot analysis (Figures 1a-c). Cell proliferation was determined by quantifying the incorporation of the thymidine analogue 5-bromo-2′-deoxyuridine (BrdU) into newly synthesized DNA of proliferating cells. U-87MG cells, transfected with SKIP siRNA or control sequences, were grown in medium containing 10% serum for 24 or 48 h before BrdU incorporation ( Figure 1d ). No difference in the percentage of BrdU-positive cells was observed in SKIP siRNA-treated cells relative to controls (P = 0.47 and 0.90 after 24 and 48 h, respectively; Figure 1e ). A feature of transformed cells is the ability to grow in the absence of serum 31 ; therefore, the effect of SKIP knockdown on cell proliferation under serum-free conditions was examined ( Figure 1d ). Knockdown of SKIP did not significantly alter the percentage of proliferating cells in serum-free conditions, compared with controls (P = 0.58 after 24 h starvation and P = 0.85 after 48 h starvation; Figure 1f ). As PI3K is activated by integrin ligation, 32 the effect of SKIP knockdown on cell proliferation was examined in response to fibronectin stimulation ( Figure 1d ). However, no statistically significant difference in cell proliferation was detected in SKIP-knockdown cells relative to controls in response to integrin ligation (P = 0.13 at 24 h stimulation and P = 0.08 at 48 h stimulation; Figure 1g ).
We next examined whether SKIP knockdown affects U-87MG cell survival by flow cytometry monitoring for annexin-V and propidium iodide staining 33 to detect apoptotic or necrotic cells. Early apoptotic cells were defined as the annexin-V-positive/ propidium iodide-negative population (lower right quadrant) and necrotic or late apoptotic cells as the annexin-V-positive/ propidium iodide-positive cells (upper right quadrant; Figure 3 ). SKIP knockdown did not significantly affect the percentage of early apoptotic cells relative to controls over four independent experiments (P = 0.15; Figure 3 ). Consistent with these findings, as a readout of PI3K activity, SKIP knockdown did not increase Akt-Ser 473 or Akt-Thr 308 phosphorylation (not shown). Collectively, these data suggest that decreased SKIP expression in PTENdeficient glioblastoma is unlikely to further enhance tumor cell survival or proliferation, consistent with the contention that SKIP depletion does not further enhance the amplified PI3K/Akt signals that occur as a consequence of PTEN loss.
SKIP overexpression inhibits anchorage-independent growth without inducing anoikis
As knockdown of SKIP did not alter glioblastoma cell proliferation or survival, the role that SKIP overexpression has in regulating PTEN-deficient cell proliferation was investigated by monitoring anchorage-independent growth, a hallmark of cell transformation. 34 Two stable U-87MG cell lines were generated that overexpressed HA-SKIP. Three control cell lines were also generated, stably reconstituted with HA-PTEN to physiological levels. 35 Exogenous PTEN was detected in HA-PTEN-reconstituted clonal cell lines, but not in the HA-SKIP-expressing cell lines or vector controls ( Figure 4a ). A 51 kDa immunoreactive polypeptide was detected in all cell lines by anti-SKIP immunoblot analysis, consistent with endogenous SKIP (Figure 4a ). HA-SKIP migrated at a slightly higher molecular weight than endogenous SKIP as detected by anti-SKIP and anti-HA immunoblot analysis and HA-SKIP was expressed at approximately threefold higher levels than endogenous SKIP. PTEN suppresses anchorage-independent growth of U-87MG cells. 36 Notably, SKIP overexpression also significantly inhibited U-87MG anchorage-independent growth, with reduced colony number and size compared with vector controls, similar to PTEN reconstitution (Figures 4b and c ).
Anoikis is a form of apoptosis induced by inadequate or inappropriate cell-matrix interactions. 37 Resistance to anoikis is critical in tumor cell transformation. 38 We evaluated whether SKIP overexpression restored anoikis, as reported for PTEN. [39] [40] [41] Following induction of cell detachment and thus anoikis using polyhydroxyethyl methacrylate (poly-HEMA), 42, 43 the viability of cells overexpressing SKIP was similar to vector controls, whereas PTEN reconstitution significantly increased cell death ( Figure 4d ). PTEN-reconstituted cells exhibited increased PARP cleavage, a marker of apoptosis, however, vector controls and SKIP-expressing cells did not ( Figure 4e ). Therefore, although both SKIP and PTEN suppress anchorage-independent growth, the phosphatases exhibit distinct regulation of anoikis.
SKIP regulates integrin-mediated cell migration
Dysregulated cell migration is a feature of cancer. 44 Although glioblastoma rarely metastasizes to secondary sites, it is locally invasive, with tumor cells penetrating and migrating into surrounding normal brain tissue, contributing to the ineffectiveness of current therapies. 2 Therefore, we investigated whether altered SKIP expression, either overexpression or knockdown, affected U-87MG cell migration. Integrin ligation activates PI3K signaling 32 and regulates PI(4,5)P 2 turnover. 45 Emerging evidence indicates that dysregulated integrin signaling contributes to disruption of cell-substratum adhesion and uncontrolled cell migration. 46 U-87MG cells exhibit defective cell polarization and increased cell migration on fibronectin. 47, 48 We assessed the impact of SKIP overexpression, in comparison with PTEN reconstitution, on the migration of fibronectin-stimulated U-87MG cells into an induced wound using time-lapse microscopy. Twenty-four hours after wound induction, vector control cells closed the wound to 9.27 μm; however, both PTENreconstituted and SKIP overexpressing cells inhibited wound closure, with wound distances remaining at 422.78 and 436.36 μm, respectively (Figures 5a and b ). Therefore, SKIP overexpression suppresses the accelerated migratory phenotype of U-87MG cells to a similar extent as PTEN reconstitution. The position of individual cells was tracked in time-lapse image series to quantify directional cell movement ( Figure 5d ). Vector control cells extended multiple membrane projections into the wound leading edge (Figure 5c , middle panels, asterisk), moving rapidly, but randomly, into the wound (Figure 5d ; Supplementary movie Figure 5 video 1.mov), consistent with previous studies in which PTEN-deficient cells, with elevated PI(3,4,5)P 3 signals, exhibit polarization defects. 49, 50 In contrast, PTEN-reconstituted cells exhibited broad directional lamellipodia at the leading edge ( Figure (Figure 5e ). Sporadically, cells projected elongated lamellipodial projections into the wound area ( Figure 5c , left panels, closed arrows), which subsequently retracted, a phenotype indicative of defective uropod release. Therefore, in glioblastoma cells overexpressing SKIP, sustained extension of lamellipodia was not maintained and failure of persistent directional migration was associated with an inability of the uropod to retract and detach from the substratum. Therefore, although both PTEN reconstitution and ectopic expression of SKIP in U-87MG cells suppressed cell migration, differences in the migratory properties of these cells were revealed.
As a subset of PTEN-deficient glioblastoma exhibited reduced SKIP protein expression ( Figure 2biv ), we also assessed the impact of SKIP knockdown on U-87MG cellular migration. U-87MG cells transfected with control siRNA closed the wound to 188.70 μm SKIP regulates integrin-mediated cytoskeletal reorganization Directional cell migration requires cytoskeletal reorganization, de novo actin nucleation and turnover of adhesion complexes. 51 PI(3,4,5)P 3 and PI(4,5)P 2 cooperatively regulate cytoskeletal remodeling and thereby cell migration. By degrading PI(3,4,5)P 3 , PTEN significantly influences cytoskeletal reorganization and directional cell migration, 49 but this has yet to be shown for SKIP, which hydrolyzes both PI(4,5)P 2 and PI(3,4,5)P 3 . 17 We therefore examined the effect of SKIP overexpression or depletion on U-87MG cytoskeletal reorganization. Vector control cells exhibited filamentous actin (F-actin) polymerization on fibronectin and multiple cell projections consistent with filopodia (Figure 7a , arrow). SKIP-overexpressing U-87MG cells showed multiple filopodial projections (Figure 7a ), but reduced F-actin staining, with cell spreading reduced by 9.8% (Figures 7a and b ). We also observed a similar actin phenotype when SKIP was overexpressed in U-251 MG and DBTRG-05MG cells (Supplementary Figure 3a) . In contrast, PTEN-reconstituted cells showed an angular morphology, decreased filopodia, prominent F-actin polymerization and a 25.4% increase in cell spreading (Figures 7a and b) . Therefore, although both PTEN and SKIP inhibit cell migration, this is mediated by distinct cytoskeletal effects. SKIP knockdown enhanced cell spreading by 25.4% and increased U-87MG cell F-actin and cortical actin polymerization (Figures 7a and b) , a phenotype rescued with the co-transfection of siRNA-resistant murine Skip complementary DNA (cDNA; Supplementary  Figure 4a ). Similar results were observed in U-251 MG and DBTRG-05MG cells with SKIP siRNA knockdown ( Supplementary  Figure 3a) . To exclude off-target effects, two independent SKIP siRNA oligonucleotides were used, resulting in similar cytoskeletal phenotypes in U-87MG cells (Supplementary Figure 4b) . The PI3K inhibitor LY294002 prevented cell spreading and F-actin polymerization in both control and SKIP-knockdown U-87MG cells, indicating these processes are downstream of PI3K ( Supplementary Figure 4c ). Focal adhesion formation was assessed using antibodies against the focal adhesion protein paxillin or talin, which links actin filaments to the cytoplasmic domain of β-integrins. 52 U-87MG vector control cells exhibited prominent paxillin or talin staining at focal adhesions, which was reduced in both number and intensity in SKIP-expressing cells (Figures 7a, c and d) . In contrast, PTEN-reconstituted cells exhibited increased paxillin-or talin-stained focal adhesions (Figures 7a, c and d) , consistent with studies showing that PTEN depletion in HeLa cells decreases F-actin and focal adhesion formation following fibronectin stimulation. 53 Focal adhesion formation was also increased in density and number in SKIPknockdown U-87MG cells, relative to controls (Figures 7a, c and d) , and also in U-251 MG and DBTRG-05MG cells with SKIP knockdown ( Supplementary Figure 3b) . Thus, both SKIP overexpression and knockdown significantly reduce integrin-mediated U-87MG cell migration, but with opposing effects on focal adhesion formation and talin incorporation into these complexes. 
SKIP and PTEN differentially regulate integrin-induced PI3K signaling
The role of PI3K signaling in SKIP-mediated regulation of cell migration was determined in response to integrin ligation, which increases plasma membrane PI(3,4,5)P 3 accumulation, leading to sustained Akt activation. 32 PTEN reconstitution in U-87MG cells suppresses fibronectin-mediated Akt activation, by dephosphorylating PI(3,4,5)P 3 signals. 41 Fibronectin-stimulated PI(3,4,5)P 3 effector plasma membrane recruitment was examined in U-87MG cells transfected with plasmids encoding green fluorescent protein (GFP)-pleckstrin homology domain of Bruton's tyrosine kinase (GFP-PH/Btk), which binds PI(3,4,5)P 3 with high affinity. 54 Within 30 min fibronectin stimulation, plasma membrane recruitment of GFP-PH/Btk was detected in vector controls (Figure 8a) . A decrease (approximately twofold) in plasma membrane biosensor recruitment was observed in PTENreconstituted cells (Figure 8b) . In contrast, SKIP did not impair biosensor plasma membrane recruitment, which was comparable in intensity and duration to vector controls (Figures 8a and b) . Akt activation was assessed as a readout of PI(3,4,5)P 3 generation by phospho-Akt-Ser 473 immunoblot analysis. Phospho-Akt-Ser 473 was not detected in serum-starved U-87MG cell suspensions, but increased on fibronectin ligation in vector controls by 15 min (Figure 8c ). PTEN reconstitution reduced Akt-Ser 473 phosphorylation two-to fivefold compared with controls following fibronectin stimulation (Figures 8c and d) ; however, ectopic expression of SKIP had no significant effect (Figures 8c and d) . Therefore, PTEN but not SKIP regulates integrin-stimulated PI(3,4,5)P 3 effector recruitment and Akt activation in U-87MG cells, which was not anticipated as SKIP suppresses insulin-stimulated PI(3,4,5)P 3 /Akt signaling in muscle cells. 14 Here, HA-SKIP localized to the plasma membrane in response to fibronectin stimulation ( Supplementary  Figure 4d ), suggesting SKIP can access its PI(3,4,5)P 3 substrate. We therefore assessed whether SKIP could suppress growth factorstimulated PI3K/Akt signaling in U-87MG cells. In response to epidermal growth factor (EGF) stimulation, increased GFP-PH/Btk at the plasma membrane was detected within 10 min in vector controls (Figure 9a ). PTEN decreased EGF-induced GFP-PH/Btk plasma membrane accumulation approximately twofold ( Figure 9b ). Importantly, HA-SKIP also attenuated EGF-mediated plasma membrane GFP-PH/Btk recruitment (~1.5-fold; Figure 9b ). Consistent with this, both SKIP and PTEN reduced basal Akt-Ser 473 phosphorylation and EGF-stimulated Akt-Ser 473 phosphorylation two-to threefold relative to vector controls (Figures 9c and d) . Therefore, ectopic expression of SKIP can suppress PI3K/Akt signaling in response to growth factors/mitogens, but not integrin ligation, for unknown reasons. SKIP regulation of integrin-induced PI3K/Akt signaling was further examined in SKIP-knockdown cells. Depletion of SKIP in PTEN-null U-87MG cells did not further increase Akt activation (not shown), suggesting PI(3,4,5)P 3 signals are maximal in this cellular context of PTEN deficiency. SKIP regulates integrin-induced PI(4,5)P 2 signals Cytoskeletal dynamics and cell migration are also regulated by PI(4,5) P 2 , a SKIP substrate. Therefore, we assessed fibronectin-mediated plasma membrane recruitment of GFP-PH/PLCδ, which binds PI(4,5) P 2 with high specificity and affinity. 55 Vector controls showed GFP-PH/PLCδ plasma membrane localization after 30 min fibronectin ligation (Figure 10a ). In contrast, ectopic expression of SKIP suppressed plasma membrane GFP-PH/PLCδ association in U-87MG cells (Figures 10a and b) . Conversely, plasma membrane PI(4,5)P 2 signals were increased in SKIP-knockdown U-87MG cells relative to controls (Figures 10c and d) and were also increased in U-251 MG and DBTRG-05 MG cells ( Supplementary Figures 5a and b) , as assessed by anti-PI(4,5)P 2 immunofluorescence microscopy. We also assessed PI(4,5)P 2 signals by the co-expression of GFP-PH/PLCδ and consistent with PI(4,5)P 2 antibody staining showed increased localization of the biosensor at the plasma membrane relative to cytosolic fluorescence in U-87MG cells (Figures 10e and f) and U-251 MG cells with SKIP siRNA knockdown ( Supplementary  Figure 5c ). Cofilin regulates actin remodeling during cell migration, binding both monomeric and F-actin with high affinity, accelerating actin monomer dissociation and increasing actin filament severing. 56 Cofilin binds PI(4,5)P 2 , however, extensive overlap of the PI(4,5)P 2 and actin-binding sites of cofilin prevents mutual binding. 57, 58 Cofilin binding to PI(4,5)P 2 recruits the protein to the plasma membrane, where subsequent PI(4,5)P 2 hydrolysis releases high localized cofilin concentrations. Cofilin is inactivated by phosphorylation at Ser 3 by LIMK, 59, 60 which prevents the protein binding to either actin or PI(4,5)P 2 , thus PI(4,5)P 2 sequesters cofilin in its active state only. Cofilin phosphorylation, as a readout of PI(4,5)P 2 signals, was examined by immunoblot analysis in integrin-stimulated cells. SKIP depletion reduced cofilin-Ser 3 phosphorylation twofold following fibronectin stimulation (Figures 10g and h) , revealing that SKIP regulates PI(4,5)P 2 signals that sequester cofilin at the plasma membrane, preventing its phosphorylation and inactivation by LIMK, so that it remains in an active state to promote actin remodeling. Therefore, SKIP suppresses fibronectin-stimulated PI(4,5)P 2 -dependent signaling to the actin cytoskeleton to impede glioblastoma cell migration.
Increased SKIP mRNA levels are associated with increased long-term survival of glioblastoma patients As SKIP overexpression or siRNA knockdown reduced glioblastoma cell migration, we investigated whether altered SKIP mRNA transcription was associated with a survival advantage in glioblastoma. Two independent data sets from ONCOMINE (www.oncomine.org), one a glioblastoma cohort in the Cancer Genome Atlas (TCGA), which contains 4400 cases, and a second cohort containing~80 glioblastoma from the Murat study, 23 were interrogated. SKIP mRNA levels in glioblastoma were grouped according to outcome data, specifically survival at 1, 3 or 5 years (Murat et al.; 23 TCGA Brain 2013, http://tcga-data. nci.gov/tcga/). Graphical representation of the microarray data sets is shown in Figure 11 . Increased SKIP mRNA levels positively correlated with increased survival at 5 years for the Murat study (P = 0.008; Figure 11a ), and at 3 and 5 years for the TCGA data set (P = 0.0005 and 0.002, respectively; Figure 11b ). Therefore, increased SKIP expression is associated with prolonged longterm survival in a subset of patients.
DISCUSSION
PTEN is frequently deleted in glioblastoma multiforme, contributing to tumor growth and progression. In this study, we established the novel finding that SKIP protein levels can be either increased or decreased in PTEN-deficient glioblastoma; one-third of PTENdeficient glioblastoma exhibited elevated SKIP protein and onethird reduced SKIP protein expression as assessed by immunohistochemistry. This is consistent with large-scale microarray data that have reported increased or decreased SKIP mRNA or DNA levels in glioblastoma relative to normal tissue. 7, 8, 10, [21] [22] [23] Here we addressed the potential impact of altered expression of the 5-phosphatase SKIP in PTEN-null glioblastoma cell lines. Our study identifies that SKIP has a significant role in regulating integrinmediated migration of PTEN-deficient glioblastoma cells. The locally invasive capacity of glioblastoma is a critical prognostic predictor. Both PTEN reconstitution and SKIP overexpression or knockdown in glioblastoma cells significantly reduced integrinmediated cancer cell migration, mediated by distinct cytoskeletal remodeling. Analysis of two independent ONCOMINE microarray transfected with control or one of two independent SKIP siRNAs. Forty-eight hours post transfection, serum-starved, suspended cells were plated onto fibronectin (10 μg/ml) for 60 min. PI(4,5)P 2 accumulation at the plasma membrane was assessed by indirect immunofluorescence using antibodies to PI(4,5)P 2 . Scale bar, 25 μm. (d) Graph represents mean ± s.e.m. PI(4,5)P 2 fluorescence intensities at the plasma membrane relative to cytosol. Greater than 90 cells were analyzed for four independent transfections. Comparison between the means was assessed using Student's t-test for unpaired data. *P o0.05 compared with control siRNA. (e) SKIP or control siRNA U-87MG cells expressing GFP-PH/ PLCδ were plated onto fibronectin (10 μg/ml) for 60 min. Scale bar, 25 μm. (f) Graph represents mean ± s.e.m. GFP-PH/PLCδ fluorescence intensities at the plasma membrane relative to cytosol. Greater than 90 cells were analyzed for three independent transfections. Comparison between the means was assessed using Student's t test for unpaired data. **P o0.01 compared with control siRNA. (g) Serum-starved suspended siRNA-transfected cells were plated onto fibronectin (10 μg/ml) for 15 min. Whole-cell lysates were subjected to immunoblot analysis using the indicated antibodies. (h) Graph shows cofilin-Ser 3 phosphorylation relative to total cofilin protein, determined by densitometry, standardized relative to control siRNA at time = 0, arbitrarily assigned a value of 1, and expressed as mean ± s.e.m. of four independent experiments. Statistical analysis was performed with one-way ANOVA followed by Tukey's post hoc test. **Po 0.01 compared with control siRNA. Figure 11 . Increased SKIP mRNA levels are associated with increased long-term survival of glioblastoma patients. Two independent data sets (Murat et al.; 23 TCGA Brain 2013) correlating SKIP mRNA transcript levels in glioblastoma with 1-, 3-or 5-year survival were obtained from ONCOMINE (www.oncomine.org). All data are log transformed and median centered. The 25th-75th percentiles are indicated within the closed blue box; the median is indicated by the solid line; the 10th and 90th percentiles are indicated by the bars. Closed circles above and below the plots show sample maximum and minimum values. The number of glioblastoma samples present in each group is shown within parentheses. Statistically significant differences in the median levels of SKIP mRNA transcription in glioblastoma outcome data reported as alive or dead at 1, 3 or 5 years were determined by a two-tailed Mann-Whitney test. (a) Increased SKIP mRNA levels correlate with increased glioblastoma 5-year survival, P = 0.008 (Murat et al. 23 ); (b) increased SKIP mRNA levels correlate with increased glioblastoma survival at 3 and 5 years, P = 0.0005 and 0.002, respectively (TCGA Brain 2013).
data sets revealed a significant correlation between increased SKIP expression in glioblastoma and improved long-term survival. Increased expression of SKIP may be associated with a survival advantage in a subset of glioblastoma associated with prolonged survival, consistent with the in vitro effects we observed in cultured glioblastoma cell lines with SKIP overexpression, including suppression of cell proliferation, anchorage-independent cell growth and cell migration. Prolonged survival beyond 3 years in glioblastoma is a rare event and in studies to date appears to be influenced by age, choice of medical treatment and the presence of specific DNA mutations and/or DNA methylation. PI(3,4,5)P 3 and PI(4,5)P 2 have complex roles in directing cytoskeletal reorganization, and thereby cell migration, via interaction with actin-regulatory proteins. In general terms, increased PI (4,5)P 2 signals, via the localized activation of type I phosphatidylinositol 4-phosphate 5-kinases (PIP5Ks), promote actin polymerization, cytoskeletal reorganization and cell migration, [61] [62] [63] [64] [65] by regulating the localization and/or activity of cytoskeletal remodeling proteins. 66 In addition, PI(4,5)P 2 directs integrin-mediated bidirectional signaling via interaction with the focal adhesionassociated protein talin, which binds the cytoplasmic domain of integrin β subunits and regulates integrin affinity for extracellular ligands. [67] [68] [69] [70] [71] PI(3,4,5)P 3 directs cell polarity, defines the leading edge of migrating cells and mediates actin reorganization via interaction with several Rho guanine nucleotide exchange factors and Rho GTPase-activating proteins. 51 PTEN regulates cell migration via degradation of PI(3,4,5)P 3 , in combination with autodephosphorylation of its lipid-binding C2 domain. [72] [73] [74] SKIP's role in regulating cancer cell migration has not been previously examined. In our studies, live cell imaging and singlecell tracking revealed prominent migratory defects in U-87MG cells with either SKIP overexpression or siRNA knockdown. We propose the molecular basis for SKIP-mediated regulation of glioblastoma cell migration on a background of PTEN deficiency and elevated PI(3,4,5)P 3 signals is mediated via the degradation of PI(4,5)P 2 . We demonstrated here increased PI(4,5)P 2 plasma membrane signals in SKIP-knockdown cells, and in contrast decreased PI(4,5)P 2 plasma membrane signals on integrin stimulation in U-87MG cells overexpressing SKIP. This is consistent with in vitro studies with respect to the substrate specificity and catalytic properties of SKIP that report a tenfold decrease in K M / V MAX for PI(4,5)P 2 as compared with PI(3,4,5)P 3 . 17 SKIP decreased integrin-stimulated F-actin polymerization and focal adhesion complexity and density, events that are directed by PI(4,5)P 2 . The formation and maturation of focal adhesion complexes is enhanced by the recruitment of PIP5Kγ to focal adhesions through an interaction with the focal adhesion protein talin, increasing kinase activity, and thus the localized generation of PI (4,5)P 2 . 75, 76 The stability of focal adhesions is further promoted on binding of talin to PI(4,5)P 2 , inducing conformational change in the protein and promoting its association with β1 integrin subunits. 69 However, negative regulators of PI(4,5)P 2 in actin cytoskeletal signaling that oppose PIP5Kγ in cancer are still emerging and here we identify SKIP as a candidate for this role. PLC-β2, which degrades PI(4,5)P 2 , is highly upregulated in breast cancer and has a critical role in cell migration and mitosis. 77 Here we report that the focal adhesion localization of talin was decreased in SKIP-expressing cells and, conversely, was increased on SKIP depletion. In addition, SKIP expression suppressed the recruitment of PI(4,5)P 2 effectors in response to integrin ligation, and in SKIP-knockdown cells, elevated plasma membrane accumulation of PI(4,5)P 2 signals correlated with reduced phosphorylation of cofilin. Lamellipodia generation is promoted and sustained by the accumulation of PI(4,5)P 2 , Cdc42 and N-WASP in phosphoinositide-rich lipid microdomains within the plasma membrane. 78 Interestingly, lamellipodial protrusions in SKIPoverexpressing U-87MG cells were initiated but not sustained, consistent with the contention that under these conditions, SKIP degrades PI(4,5)P 2 to inhibit glioblastoma cell migration. In contrast, PTEN-mediated hydrolysis of PI(3,4,5)P 3 generates PI (4,5)P 2 , an allosteric activator of PTEN. 79 The PI(4,5)P 2 -binding motif at the amino-terminal of PTEN localizes the enzyme to the plasma membrane and regulates its activity during chemotaxis. 80 In PTEN-deficient cells, PI(3,4,5)P 3 signals and Akt activation are both increased and sustained. Here, knockdown of SKIP in PTENdeficient cells did not further increase PI3K/Akt signaling. This does not exclude the possibility that SKIP degrades PI(3,4,5)P 3 in vivo, as this has been shown in insulin-sensitive cells, 14 and here ectopic expression of SKIP reduced growth factor-stimulated PI (3,4,5)P 3 biosensor recruitment, Akt-Ser 473 phosphorylation and anchorage-independent growth. Therefore, we conclude that in PTEN-deficient cells, PI(3,4,5)P 3 signals are maximal and cannot be further amplified, even with loss of SKIP, a known PI(3,4,5)P 3 5-phosphatase. In addition, we observed that SKIP showed little ability to regulate PI3K/Akt signaling in response to integrin activation, despite showing SKIP plasma membrane recruitment, implying the enzyme can access its phosphoinositide substrate. The molecular basis for these observations remains unclear and is the subject of ongoing investigations.
In conclusion, our investigations reveal that SKIP is a significant regulator of glioblastoma cell migration and that increased expression of SKIP may confer a survival advantage. We propose that in the context of PTEN depletion, and consequent elevation of PI(3,4,5)P 3 signals, SKIP regulates cytoskeletal reorganization and glioblastoma cell migration via hydrolysis of PI(4,5)P 2 .
MATERIALS AND METHODS
Antibodies and constructs GFP-PH/Btk and GFP-PH/PLCδ constructs were provided by Tamas Balla (NIH, Bethesda, MA, USA). Antibodies include: SKIP, 12 PTEN (Merck-Millipore, Billerica, MA, USA), HA (Covance, Princeton, NJ, USA), β-tubulin (Life Technologies, Mulgrave, VIC, Australia), talin (Sigma-Aldrich, St Louis, MO, USA), paxillin (BD Biosciences, San Diego, CA, USA) and PI(4,5)P 2 (Echelon Biosciences, Salt Lake City, UT, USA). All other antibodies were purchased from Cell Signaling Technology.
Immunohistochemistry of human glioblastoma tissue
Antigen retrieval of SKIP or PTEN on human glioblastoma tissue arrays (US Biomax) was performed at 120°C for 10 min using 10 mMTris/1 mM EDTA (pH 9) or at 120°C for 30 min using 10 mM citrate (pH 6), respectively, followed by incubation with anti-SKIP 12 (2 μg/ml) or anti-PTEN (1:50 dilution; clone 138G6) overnight at 4°C. Images were obtained by light microscopy (AX70 Provis, Olympus, Center Valley, PA, USA) with a × 10 UPlanApo NA 0.4 dry or × 40 UPlanApo NA 1.00 oil immersion objective lens and digitally captured (Olympus DP70).
Generation of stable cell lines and transient transfections
U-87 MG, U-251 MG and DBTRG-05MG cells were obtained from ATCC (Manassas, VA, USA) or ECACC (Porton Down, Salisbury, UK). U-87MG cells were electroporated with full-length HA-SKIP-pCI-Neo and stable clones selected in G418 (1.5 mg/ml; A.G. Scientific, San Diego, CA, USA). Retroviralmediated generation of HA-PTEN-pBABE(puro) U-87MG cell lines was performed as described. 35 U-251 MG or DBTRG-05MG cells were transiently transfected with full-length HA-SKIP-pCI-Neo or HA-pCI-Neo using Lipofectamine 2000 (Life Technologies) according to manufacturer's instructions. U-87 MG, U-251 MG or DBTRG-05MG cells were transiently transfected with one of two siRNA oligonucleotides (Qiagen; Venlo, The Netherlands) using X-tremeGENE siRNA transfection reagent (Roche Diagnostics, Castle Hill, NSW, Australia) according to manufacturer's instructions. SKIP siRNA#1: 5′-GCCAAGUGUCGUCCACAUA-3′. SKIP siRNA#2: 5′-GGAAUUAGCCGCUUAAAUATT-3′.
Quantitative reverse transcriptase-PCR
RNA was isolated (RNeasy RNA extraction kit; Qiagen) and reverse transcribed (AffinityScript QPCR cDNA Synthesis Kit; Integrated Sciences, Chatswood, NSW, Australia). cDNA was analyzed using SKIP primers (Hs_SKIP_1_SG QuantiTect Primer Assay; Qiagen), with β-actin (Hs_ACTB_1_SG QuantiTect Primer Assay; Qiagen) or GAPDH (Hs_GAPDH_1_SG QuantiTect Primer Assay; Qiagen) as endogenous controls. Cycling was performed using Brilliant II SYBR Green QPCR master mix (Integrated Sciences) with Rotor-Gene3000 (Corbett Research, Sydney, NSW, Australia). Differential expression was determined using the comparative ΔΔC T method. 81 Cell proliferation assay Cells were maintained in media containing 10% fetal bovine serum, in serum-free media or plated onto fibronectin-coated (10 μg/ml) plates, before treatment with BrdU according to manufacturer's instructions (Roche Diagnostics). Images were obtained by fluorescence microscopy (Olympus IX71) with a × 10 Cplan FL NA 0.3 RC1 dry objective lens.
Fluorescence-activated cell sorting
Cells were collected with 1 mM EDTA and incubated with annexin-V-FLUOS (Roche Diagnostics) according to manufacturer's instructions. Data were collected (FACSCalibur flow cytometer; BD Biosciences) and analyzed (CELLQuest; BD Biosciences or FlowJo 7; Treestar Inc. software, Ashland, OR, USA). Fluoroscein isothiocyanate and propidium iodide emissions were acquired through 515 and 4600 nm bandpass filters, respectively. A minimum of 5000 events per analysis was recorded.
Soft agar studies
Colony formation was evaluated by overlaying 0.7% agarose with DMEM supplemented with 10% fetal bovine serum and 0.3% agarose containing 2 × 10 3 cells. After 14 days, colonies were stained with 0.1% gentian violet.
Localization of plasma membrane PI(3,4,5)P 3 and PI(4,5)P 2 Cells were transfected with GFP-PH/Btk 54 or GFP-PH/PLCδ 55 using Lipofectamine (Life Technologies). Serum-starved adherent cells were treated with 100 ng/ml EGF (BD Biosciences). Alternatively, cells were collected with EDTA (1 mM) and held in suspension for 30 min, before plating onto fibronectin-coated coverslips (10 μg/ml). Single z-plane images were obtained by confocal laser scanning microscopy (FV1000, Olympus; TCS-NT SP5, Leica, Wetzlar, Germany) with a × 60 Plan-Apochromat NA 1.4 or × 40 HCX Plan-Apochromat NA 1.25 λBL oil immersion objective lens and analyzed using Image J software. 82 Quantification of plasma membrane GFP-PH/Btk or GFP-PH/PLCδ recruitment was determined by measuring the average pixel fluorescence intensity within an area of defined size drawn over three distinct areas of the plasma membrane (5 × 10 pixels) or the average of three boxes (10 × 10 pixels) in the cytosol, and expressed as ratios of plasma membrane to cytosolic pixel fluorescence intensity. 83 
Immunoblot analysis
Serum-starved adherent cells were treated with EGF (100 ng/ml). Alternatively, cells were detached with EDTA (1 mM), held in suspension for 30 min and plated onto fibronectin-coated plates (10 μg/ml). Nonidet P-40 (NP-40)-soluble cell fractions or whole-cell lysates were resolved by SDS-polyacrylamide gel electrophoresis. Relative protein levels were assessed by densitometry (GelPro analyzer or ImageQuant TL software, GE Healthcare (Little Chalfont, UK)).
Anoikis induction
Anoikis was induced by poly-HEMA culture as previously described. 42 Serum-starved cells were plated onto poly-HEMA-coated plates at a density of 1 × 10 5 cells/ml. Cell viability was determined by Trypan blue exclusion. Triton X-100-soluble cell fractions, prepared from 48 h poly-HEMA cell cultures, were subjected to immunoblot analysis.
Indirect immunofluorescence
Serum-starved cells were collected with 1 mM EDTA and plated onto fibronectin-coated (10 μg/ml) coverslips. Focal adhesion formation was assessed with paxillin or talin antibodies. F-actin was visualized with Texas Red or Alexa Fluor 488-conjugated phalloidin (Life Technologies). Plasma membrane PI(4,5)P 2 accumulation was assessed as previously described. 84 Single z-plane images were obtained by confocal laser scanning microscopy (TCS-NT SP5, Leica) with a × 40 HCX Plan-Apochromat NA 1.25 λBL or × 100 HCX Plan-Apochromat NA 1.4 CS oil immersion objective lens. Quantification was performed in more than 90 cells over a minimum of three independent experiments using Image J software, 82 determined by measuring the average pixel fluorescence intensity within an area of defined size drawn over three distinct areas of the plasma membrane (5 × 10 pixels) or the average of three boxes (10 × 10 pixels) in the cytosol, and expressed as ratios of plasma membrane to cytosolic pixel fluorescence.
Cell migration
Cells were grown to confluence on fibronectin-coated (10 μg/ml) tissue culture plates before wound induction. Phase contrast images were collected at 37°C, 5% CO 2 (AF6000LX; Leica) using a × 10 NA 0.30 PH1 dry objective lens at 30 min time intervals. Image processing was performed using MetaMorph (Molecular Devices Corporation, Sunnyvale, CA, USA) or Image J software. 82 
ONCOMINE data
The ONCOMINE database was searched for data sets in which SKIP mRNA levels in glioblastoma were grouped according to patient survival. Primary sources for the glioblastoma data from ONCOMINE (www.oncomine.org) were from Murat et al. 23 and TGCA Brain 2013. Data sets were identified and representative box plots shown to illustrate the difference in SKIP mRNA transcription within cohorts. All data are log transformed and median centered. Significance between median SKIP mRNA levels was determined by a two-tailed Mann-Whitney test.
Statistical analysis
Statistical significance of comparison between the means of two groups was assessed using Student's t-test for unpaired data. Significance of multiple comparisons of sample means was performed by one-way analysis of variance followed by a Tukey's post hoc test. Comparison of median survival between groups was performed by a two-tailed Mann--Whitney test. P-values o0.05 were considered statistically significant.
